摘要:
The present disclosure provides adeno-associated virus (AAV) virions with altered capsid protein, where the AAV virions exhibit greater infectivity of retinal cells, when administered via intravitreal injection, compared to wild-type AAV. The present disclosure further provides methods of delivering a gene product to a retinal cell in an individual, and methods of treating ocular disease.
摘要:
The present disclosure provides adeno-associated virus (AAV) virions with altered capsid protein, where the AAV virions exhibit greater infectivity of retinal cells, when administered via intravitreal injection, compared to wild-type AAV. The present disclosure further provides methods of delivering a gene product to a retinal cell in an individual, and methods of treating ocular disease.
摘要:
The present invention provides methods and compositions for the treatment of disease of the eye, such as retinitis pigmentosa (RP) and glaucoma, by delivery of a transgene encoding a therapeutic polypeptide, such as glial cell-derived neurotrophic factor (GDNF), specifically to Müller glial cells using a gene delivery vector. In one embodiment, the gene delivery vector is a pseudotyped retroviral vector, particularly a lentiviral vector.
摘要:
Gene delivery vectors, such as, for example, recombinant adeno-associated viral vectors, and methods of using such vectors are provided for use in treating or preventing diseases of the eye.
摘要:
Gene delivery vectors, such as, for example, recombinant adeno-associated viral vectors, and methods of using such vectors are provided for use in treating or preventing diseases of the eye.